Resultados de la búsqueda 1-10 of 14123 for Emicizumab

  1. Bispecific antibody therapy

    Other diseases. Emicizumab (Hemlibra) binds factor IXa and factor X proteins to help prevent bleeding in people with hemophilia A. Faricimab (Vabysmo) blocks ...

  2. Bispecific antibody therapy - Mayo Clinic

    Other diseases. Emicizumab (Hemlibra) binds factor IXa and factor X proteins to help prevent bleeding in people with hemophilia A. Faricimab (Vabysmo) blocks ...

  3. Hematología - Ensayos clínicos - Mayo Clinic

    The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS) ...

  4. Hematología - Ensayos clínicos - Mayo Clinic

    This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The performance characteristics of the ddPCR assay for the detection of ctDNA mutation in uveal melanoma patients will be assessed by comparing the mutation ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  10. Hematología - Ensayos clínicos - Mayo Clinic

    This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...